QLS1410 in Participants With Uncontrolled Hypertension
Condition(s) studied
Investigational drug(s) / intervention(s)
Dose 1 of QLS1410: QLS1410 tablet administered orally, once daily (QD).
Dose 2 of QLS1410: QLS1410 tablet administered orally, once daily (QD).
Dose 3 of QLS1410: QLS1410 tablet administered orally, once daily (QD).
placebo: Matching placebo tablet administered orally, once daily (QD).
Study summary
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure(SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.
Eligibility
Primary outcome measure(s)
- Change from baseline in mean seated systolic blood pressure (SBP) at week 12 — At week 12
To assess the effect of QLS1410 versus placebo on the mean seated systolic blood pressure (SBP) at week 12
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Qilu Hospital of Shandong University | Jinan | China |
More Qilu Pharmaceutical Co., Ltd. trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07489612 on ClinicalTrials.gov ↗ ← All trials in China